KIORA PHARMACEUTICALS INC

What they do

Kiora develops small-molecule therapies for retinal diseases. KIO-301, acquired via Bayon Therapeutics in October 2021, is a 'photoswitch' small molecule intended to restore light sensitivity in patients with late-stage retinitis pigmentosa; it is in the Phase 2 ABACUS-2 trial. KIO-104, acquired via Panoptes Pharma in 2020, is an intravitreal DHODH inhibitor for retinal inflammatory diseases including macular edema; it is in the Phase 2 KLARITY trial. A third asset, KIO-101, is a topical formulation of the KIO-104 compound being considered for partnering.

Revenue drivers

• Théa Open Innovation license (KIO-301) — January 2024 agreement granting exclusive worldwide rights excluding Asia; Kiora received a $16 million upfront payment, up to $285 million in clinical, regulatory and commercial milestones, tiered royalties up to the low 20% range on net sales, and reimbursement of all KIO-301 R&D expenses going forward.
• Senju option (KIO-301, Asia) — May 2025 exclusive option agreement covering Japan, China and other select Asian countries; Kiora received a nonrefundable $1.25 million payment and would be eligible for an additional $109.5 million plus tiered royalties up to the high teens if the option is exercised and a license executed.
• Product sales — None. No product is approved or marketed; recent quarterly revenue was $0.00 for each quarter of 2025, and annual revenue was $0.00 in 2021, 2023 and 2025 against $16.0 million in 2024, which reflects the Théa upfront payment.

Recent performance

Kiora reported second quarter 2026 results on August 7, 2026, ending the quarter with approximately $16.8 million in cash and short-term investments, up from $13.9 million at March 31, 2026, primarily on the strategic equity financing completed in the quarter. Research and development expenses were approximately $2.1 million for the quarter before recognizing $1.3 million in reimbursement. The company also recorded approximately $1.1 million in collaboration receivables and $1.8 million in tax and other receivables at June 30, 2026. Reported balance sheet data at June 30, 2026 show total assets of $23.8 million, total liabilities of $6.9 million and shareholder equity of $16.9 million. Revenue has been $0.00 in each quarter of 2025.

Strategy

Kiora is advancing KIO-301 through the 36-patient, double-masked, randomized Phase 2 ABACUS-2 trial in late-stage retinitis pigmentosa, with development costs fully reimbursed by Théa Open Innovation. Enrollment has moved into the higher 100 microgram dose cohort, followed by a predefined independent safety review before the remaining patients enroll; the company targets last-patient-first-visit in the first quarter of 2027 and topline data in the third quarter of 2027. For KIO-104, the company is enrolling the higher-dose cohort of the Phase 2 KLARITY trial in macular edema due to retinal inflammation and expects initial data in late 2026. Management states it is evaluating potential strategic transactions that could diversify the pipeline and, if completed by early next year, would satisfy a warrant acceleration milestone under the recent private placement.

Risks

• No product revenue and recurring losses — Kiora has no approved product and reported $0.00 revenue in each quarter of 2025, with annual net income of -$10,835 in 2025 and -$12,514 in 2023.
• Dependence on two candidates — The 10-K risk factors state the company depends heavily on the future success of KIO-104 and KIO-301, and failure to obtain marketing approval or commercialize either would materially harm the business.
• Need for additional capital — The 10-K states Kiora will need substantial additional funding and that failure to raise capital when needed could force it to delay, reduce or eliminate development programs.
• Clinical and regulatory uncertainty — ABACUS-2 and KLARITY are ongoing Phase 2 trials; the 10-K warns that if trials fail to demonstrate safety and efficacy to FDA or foreign regulators, development and commercialization could be delayed or unable to complete.

Outlook

Management expects KIO-301 ABACUS-2 last-patient-first-visit in the first quarter of 2027 and topline data in the third quarter of 2027, and initial KIO-104 KLARITY clinical data in late 2026. Théa reimburses all KIO-301 ABACUS-2 research and development expenses. Kiora states that current resources, expected collaboration reimbursements and available capital should fund operations into late 2028. The company is evaluating strategic transactions that, if completed by early next year, would trigger a warrant acceleration provision under its private placement and potentially provide additional capital.